LH (Labcorp Holdings) Beginning Cash Position : $1,517 Mil (As of Dec. 2024)

View and export this data going back to 1991. Start your Free Trial

What is Labcorp Holdings Beginning Cash Position?

Labcorp Holdings's Beginning Cash Position for the quarter that ended in Dec. 2024 was $1,517 Mil.

Labcorp Holdings's quarterly Beginning Cash Position increased from Jun. 2024 ($99 Mil) to Sep. 2024 ($265 Mil) and increased from Sep. 2024 ($265 Mil) to Dec. 2024 ($1,517 Mil).

Labcorp Holdings's annual Beginning Cash Position declined from Dec. 2022 ($1,363 Mil) to Dec. 2023 ($430 Mil) but then increased from Dec. 2023 ($430 Mil) to Dec. 2024 ($537 Mil).

Labcorp Holdings Beginning Cash Position Historical Data

The historical data trend for Labcorp Holdings's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Labcorp Holdings Beginning Cash Position Chart

Labcorp Holdings Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Beginning Cash Position

Get a 7-Day Free Trial

337.50

1,229.50

1,363.30

430.00

536.80

Labcorp Holdings Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Beginning Cash Position	Get a 7-Day Free Trial															727.90	536.80	99.30	265.10	1,517.30

Labcorp Holdings Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Labcorp Holdings Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Labcorp Holdings's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Labcorp Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Labcorp Holdings Inc (NYSE:LH) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

LH:Mexico 0JSY:UK N6B:Germany

Address

358 South Main Street, Burlington, NC, USA, 27215

Website

https://www.labcorp.com

Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.

Executives

Amy B. Summy	officer: EVP, Chief Marketing Officer	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Mark S Schroeder	officer: EVP, President-Diagnostics Lab	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Kerrii B Anderson	director	WENDY'S INTERNATIONAL, INC, 4288 WEST DUBLIN-GRANVILLE RD., DUBLIN OH 43017
Van Der Vaart Sandra D	officer: SVP, Global General Counsel	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Adam H Schechter	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Dwight Gary Gilliland	director	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Glenn A Eisenberg	officer: Chief Financial Officer, EVP	P O BOX 1017, CHARLOTTE NC 28201-1017
Lance Berberian	officer: SVP, Chief Information Officer
Peter J Wilkinson	officer: SVP, Chief Accounting Officer	C/O PHARMACEUTICAL PRODUCT DEVELOPMENT, 929 NORTH FRONT STREET, WILMINGTON NC 28401
Paul Rothman	director	6 MEADOW ROAD, BALTIMORE MD 21212
Paul R Kirchgraber	officer: CEO, Covance Drug Development	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Megan D. Bailey	officer: EVP, Chief Strategy Officer	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Jonathan P. Divincenzo	officer: EVP, Pres, Central Labs & Intl	940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451
Anita Z Graham	officer: EVP, CHRO	C/O THE ADT CORPORATION, 1501 YAMATO ROAD, BOCA RATON FL 33431
Thomas Pike	officer: Pres & CEO Clinical Business	C/O ACCENTURE, 161 N. CLARK STREET, 23RD FLOOR, CHICAGO IL 60601